M&As this week: WIRB-Copernicus, AbCellera Biologics, Apricus Biosciences

3rd August 2018 (Last Updated August 3rd, 2018 00:00)

WIRB-Copernicus Group has completed the acquisition of KMR Group and Metrics Champion Consortium (MCC) for an undisclosed sum.

WIRB-Copernicus Group has completed the acquisition of KMR Group and Metrics Champion Consortium (MCC) for an undisclosed sum.

The acquired companies will operate under the WCG Market Insights and Intelligence division, as part of the transaction.

WIRB-Copernicus is a provider of transformative solutions to the clinical research industry, while KMR and MCC specialise in providing metrics, analytics and performance benchmarking to the clinical trials industry.

All companies involved in the transaction are based in the US.

AbCellera Biologics has completed the acquisition of Lineage Biosciences in an all-stock transaction.

AbCellera Biologics will gain exclusive rights for immune repertoire sequencing (Ig-SEQ) of Lineage Biosciences, through the transaction. Ig-SEQ is used for carrying out deep analysis of antibodies, which are produced by natural immune responses.

Based in Canada, AbCellera Biologics is a therapeutics company engaged in the discovery of antibodies, while Lineage Biosciences is a US-based company involved in the provision of technology for the profiling of antibody responses using next-generation sequencing.

"AbCellera Biologics has completed the acquisition of Lineage Biosciences in an all-stock transaction."

The transaction enables the acquirer company to expand its capabilities in the discovery of antibodies and vaccine research.

Apricus Biosciences has signed a definitive merger agreement with Seelos Therapeutics in an all-stock transaction.

The combined company will focus on the advancement of late-stage pipeline products for central nervous system (CNS) disorders.

The combined entity will be operated under the name, Seelos Therapeutics, upon completion of the merger transaction.

Apricus is a biopharmaceutical company focused on the development of innovative medicines in the fields of urology and rheumatology, while Seelos Therapeutics is a clinical-stage biopharmaceutical company engaged in the development of novel therapeutics for unmet medical needs.

Both companies involved in the transaction are based in the US.

The merger transaction enables both the companies to develop and commercialise novel therapeutics for patients with CNS disorders.